Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives

US6267964A · kind A · utility

Assignee

• Affibody Technology Sweden AB · SE

Inventors

• Per Nygren · Helsingborg, SE
• Hans Wigzell · Stuvsta-Snättringe, SE
• Mathias Uhlen · Uppsala, SE

Key dates

• Filing date: Dec 8, 1993
• Grant date: Jul 31, 2001
• Expiry date: Dec 8, 2013

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A process for extending the half-life in vivo by a biologically active protein or peptide, characterized by covalently coupling said protein or peptide to a polypeptide fragment capable of binding to a serum protein, whereby when administering the resulting protein or peptide conjugate its binding to the serum protein results in extended biological activity, the use of the protein or peptide conjugate above for manufacturing a medicament which, when administered to a mammal including man, shows extended half-life in vivo; and a method of therapeutic or prophylactic treatment.